CUSIP: 40434H104
Q2 2020 13F Holders as of 30 Jun 2020
-
Type / Class
-
Equity / COM
-
Total 13F shares
-
13,755,353
-
Share change
-
-1,394,987
-
Total reported value
-
$9,904,000
-
Price per share
-
$0.72
-
Number of holders
-
24
-
Value change
-
+$52,851
-
Number of buys
-
15
-
Number of sells
-
12
Quarterly Holders Quick Answers
What is CUSIP 40434H104?
CUSIP 40434H104 identifies HTGM - HTG MOLECULAR DIAGNOSTICS IN - COM in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
-
Newer quarter:
Q3 2020
-
Previous quarter:
Q1 2020
Recent filing periods for CUSIP 40434H104:
Institutional Holders of HTG MOLECULAR DIAGNOSTICS IN - COM (HTGM) as of Q2 2020
As of 30 Jun 2020,
HTG MOLECULAR DIAGNOSTICS IN - COM (HTGM) was held by
24 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
13,755,353 shares.
The largest 10 holders included
Nantahala Capital Management, LLC, Cowen Prime Services LLC, VANGUARD GROUP INC, RENAISSANCE TECHNOLOGIES LLC, BlackRock Inc., GEODE CAPITAL MANAGEMENT, LLC, WINTON GROUP Ltd, NORTHERN TRUST CORP, Kalos Management, Inc., and Qube Research & Technologies Ltd.
This page lists
24
institutional shareholders reporting positions in this security
for the Q2 2020 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.